
CardiaCare Completes Successful First In Human Clinical Trial of Home-Care treatment for Atrial Fibrillation
CardiaCare successfully completed it’s First in Human Clinical trial in Atrial Fibrillation (AF) patients arriving to the emergency room of the Chaim Sheba Medical Center. Patients have received the CardiaCare RR2 device for 8 weeks of home-care neuromodulation therapy and monitoring. The results demonstrated a high device safety profile, a significant acute reduction in AF precursor arrythmia events as well as long term reduction in AF recurrence rates after discharge from the hospital. In this real-life population study the home-care compliance with with device monitoring and therapeutic capabilities was extremely high.